MiCLASP Post Market Clinical Follow-Up (PMCF) Study (MiCLASP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
This is a postmarket clinical follow up study on the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in transcatheter mitral valve repair.
Condition or disease
Mitral RegurgitationMitral Insufficiency
Device: Edwards PASCAL Transcatheter Valve Repair System
The objectives of this clinical study are to collect data on the safety of the Edwards PASCAL Transcatheter Valve Repair System in transcatheter mitral valve repair and on the effectiveness of the Edwards PASCAL System in improving MR and improving functional status and quality of life in a post market setting.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients at or over the age of 18 determined to require percutaneous reconstruction of an insufficient mitral valve (MR ≥ 2+) by a Heart Team who assesses patient risk and anatomic suitability should be considered for inclusion in this trial.
Age greater than or equal to 18 years
Patient is determined to require percutaneous reconstruction of an insufficient mitral valve (MR greater than or equal to 2+ ) by a Heart Team who assesses patient risk and anatomic suitability.
Patient is eligible to receive the PASCAL device per the current approved indications for use.
Minimum 6 minutes walk test of 150m. This criteria applies only to patients presenting with primarily functional mitral valve regurgitation.
Patient is willing and able to attend all follow up visits and to perform all tests.
Patient in whom a transesophageal echocardiography is contraindicated or screening transesophageal echocardiography is unsuccessful
Leaflet anatomy which may preclude PASCAL device implantation, proper device positioning on the leaflets, or sufficient reduction in mitral regurgitation
Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
LVEDD > 8.0 cm determined by transthoracic echocardiography within 60 days prior to submission
Contraindication to transseptal catheterization
Presence of an occluded or thrombosed Inferior vena cava filter that would interfere with the delivery catheter, or ipsilateral deep vein thrombosis is present.
Mitral valve area (MVA) < 4.0 cm² as measured by planimetry (If MVA by planimetry is not measurable, PHT measurement is acceptable)
Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator